Search

NICE recommends epcoritamab for DLBCL

Standard post

… epcoritamab as an option for treating relapsed or refractory  diffuse large B-cell lymphoma (DLBCL)  in adults … for lymphoma. … New treatment available for relapsed or refractory diffuse large B-cell lymphoma. … NICE recommends …

NICE recommends glofitamab for DLBCL

Standard post

… glofitamab as an option for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults … for lymphoma.   … New treatment available for relapsed or refractory diffuse large B-cell lymphoma. … NICE recommends …

Tafasitamab with lenalidomide not recommended

Standard post

… tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or primary … place (including Axicabtagene ciloleucel for relapsed or refractory diffuse large B-cell lymphoma or primary … recommend tafasitamab with lenalidomide for relapsed or refractory diffuse large B-cell lymphoma … Tafasitamab with …

SMC recommends two new treatment options for DLBCL

Standard post

… for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) , after two … a study showed that 40% of patients with relapsed or refractory DLBCL had a complete response after receiving it … a study showed that 62% of patients with relapsed or refractory DLBCL treated with it had an objective response. …

Encouraging results for new treatments in DLBCL

Standard post

… (DLBCL) that has come back (relapsed) or not responded (refractory) after initial therapy can be difficult to treat. … could be beneficial for people with relapsed or refractory DLBCL who are not able to have a stem cell … of durable complete responses for people with relapsed or refractory DLBCL who are not able to have a stem cell …

CAR-T cell therapy available for mantle cell lymphoma

Standard post

… lymphoma that has come back (relapsed) or not responded (refractory) after at least two previous courses of treatment, … cure. This is an important day for people with relapsed or refractory MCL who, until now, had limited treatment options … cell therapies are already available to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or primary …

NICE recommends Loncastuximab tesirine for DLBCL

Standard post

… tesirine as an option for treating relapsed or refractory  diffuse large B-cell lymphoma (DLBCL)  and … … New third line treatment available for relapsed or refractory diffuse large B-cell lymphoma. … NICE recommends …

NICE recommends CAR-T cell therapies for lymphoma

Standard post

… but whose lymphoma has relapsed (come back) or was refractory (did not respond to treatment). Axicabtagene … ciloleucel is also recommended for people with relapsed or refractory primary mediastinal large B-cell lymphoma who have … offers a potential lifeline for people with relapsed or refractory DLBCL or primary mediastinal large B ‑ cell …

Promising results for new oral treatment in DLBCL

Standard post

… (DLBCL) that has come back (relapsed) or not responded (refractory) after at least two previous courses of therapy … oral treatment called selinexor in people with relapsed or refractory DLBCL who had already had between two and five … a potential new oral treatment for people with relapsed or refractory DLBCL who otherwise have very limited treatment …